Report period | 2018 | 2019 | 2020 | 2021 | 2022 | Q3 23 |
---|---|---|---|---|---|---|
End date of the reporting period | ||||||
Capitalization, $ | ||||||
Capitalization, $ | ||||||
Enterprise Value | ||||||
Book Value | ||||||
Shareholders Book Value | ||||||
Current liabilities | ||||||
Noncurrent liabilities | ||||||
Total liabilities | ||||||
Debt | ||||||
Cash and cash equivalents | ||||||
Net debt | ||||||
Assets | ||||||
Total ordinary shares | ||||||
Ordinary share price |
Ticker | Name | Type | Nominal value | ISIN | Price |
---|---|---|---|---|---|
BIO:US | Bio-Rad Laboratories, Inc. | Common share | - | US0905722072 | $320.3 |
Company name | Bio-Rad Laboratories |
---|---|
Tags | #medtech, #s&p500 index |
Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Life Sciences Tools & Services / Life Sciences Tools & Services |
Business address | 1000 ALFRED NOBEL DRIVE HERCULES CA 94547 5107247000 |
Mailing address | 1000 ALFRED NOBEL DRIVE HERCULES CA 94547 |
Website | www.bio-rad.com |
Information disclosure | www.sec.gov |